Rebecca Kirby

Ms. Rebecca Kirby

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
BGBirgitta Gleeson
Birgitta Gleeson
CFCecilia Ferreyra
Cecilia Ferreyra
KPKara Palamounta
Kara Palamounta
SJShevin T Jacob
Shevin T Jacob
NSNaomi Spotswood
Naomi Spotswood
SLSara Liaghati-Mobarhan
Sara Liaghati-Mobarhan

15 November 2023 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
RKRebecca Kirby
Rebecca Kirby
EMElizabeth M. Molyneux
Elizabeth M. Molyneux
QDQueen Dube
Queen Dube
CMCindy McWhorter
Cindy McWhorter
BBBeverly D. Bradley
Beverly D. Bradley
KPKara M. Palamountain
Kara M. Palamountain
Background: Medical devices are critical to providing high-quality, hospital-based newborn care, yet many of these devices are unavailable in low- and middle-income countries (LMIC) and are not designed to be suitable for these settings. Target Product Profiles (TPPs) are often utilised at an early stage in the medical device development process to enable user-defined performance characteristics for a given setting. TPPs can also be applied to assess the profile and match of existing devices for a given context. Methods: We developed initial TPPs for 15 newborn product categories for LMIC settings. A Delphi-like process was used to develop the TPPs. Respondents completed an online survey where they scored their level of agreement with each of the proposed performance characteristics for each of the 15 devices. Characteristics with < 75% agreement between respondents were discussed and voted on using Mentimeter™ at an in-person consensus meeting. Findings: The TPP online survey was sent to 180 people, of which 103 responded (57%). The majority of respondents were implementers/clinicians (51%, 53/103), with 50% (52/103) from LMIC. Across the 15 TPPs, 403 (60%) of the 668 performance characteristics did not achieve > 75% agreement. Areas of disagreement were voted on by 69 participants at an in-person consensus meeting, with consensus achieved for 648 (97%) performance characteristics. Only 20 (3%) performance characteristics did not achieve consensus, most (15/20) relating to quality management systems. UNICEF published the 15 TPPs in April 2020, accompanied by a report detailing the online survey results and consensus meeting discussion, which has been viewed 7,039 times (as of January 2023). Conclusions: These 15 TPPs can inform developers and enable implementers to select neonatal care products for LMIC. Over 2,400 medical devices and diagnostics meeting these TPPs have been installed in 65 hospitals in Nigeria, Tanzania, Kenya, and Malawi through the NEST360 Alliance. Twenty-three medical devices identified and qualified by NEST360 meet nearly all performance characteristics across 11 of the 15 TPPs. Eight of the 23 qualified medical devices are available in the UNICEF Supply Catalogue. Some developers have adjusted their technologies to meet these TPPs. There is potential to adapt the TPP process beyond newborn care.

17 July 2023 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
PDF file
RKRebecca Kirby
Rebecca Kirby
AMAeesha N J Malik
Aeesha N J Malik
KPKara M Palamountain
Kara M Palamountain
CGClare E Gilbert
Clare E Gilbert
Background As more preterm infants survive, complications of preterm birth, including retinopathy of prematurity (ROP), become more prevalent. ROP rates and blindness from ROP are higher in low-income and middle-income countries, where exposure to risk factors can be higher and where detection and treatment of ROP are under-resourced or non-existent. Access to low-cost imaging devices would improve remote screening capabilities for ROP. Methods Target product profiles (TPPs) are developed early in the medical device development process to define the setting, target user and range of product requirements. A Delphi-like process, consisting of an online survey and consensus meeting, was used to develop a TPP for an ROP imaging device, collecting feedback on a proposed set of 64 product requirements. Results Thirty-six stakeholders from 17 countries provided feedback: clinicians (72%), product developers (14%), technicians (6%) and other (8%). Thirty-six per cent reported not currently screening for ROP, with cited barriers including cost (44%), no training (17%) and poor image quality (16%). Among those screening (n=23), 48% use more than one device, with the most common being an indirect ophthalmoscope (87%), followed by RetCam (26%) and smartphone with image capture (26%). Consensus was reached on 53 (83%) product requirements. The 11 remaining were discussed at the consensus meeting, and all but two achieved consensus. Conclusions This TPP process was novel in that it successfully brought together diverse stakeholders to reach consensus on the product requirements for an ROP imaging devices. The resulting TPP provides a framework from which innovators can develop prototypes.

23 October 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
YMYukari C Manabe
Yukari C Manabe
MHMatthew M Hamill
Matthew M Hamill
KPKara Palamounta
Kara Palamounta
CAChad J Achenbach
Chad J Achenbach
KDKevin P Delaney
Kevin P Delaney
DKDavid A Katz
David A Katz
In global settings, both the clinical use case and value proposition have been well articulated. This has led to the development of many point-of-care (POC) diagnostics for infectious diseases. However, in the United States, more than 80% of infectious disease diagnostics are performed in reference laboratories that have high throughput but relatively long turnaround times. As the cost of POC assays has decreased with nucleic acid test (NAT) innovation catalyzed by the coronavirus disease 2019 pandemic, we sought to develop clinical use cases for human immunodeficiency virus (HIV) NATs and the technical specifications that would tip the value proposition toward commercialization and meaningful adoption. Without POC HIV NATs, we are unlikely to achieve our collective goal of HIV elimination in the United States.

13 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RKRebecca Kirby
Rebecca Kirby
MMMichal Maimaran
Michal Maimaran
KPKara M Palamountain
Kara M Palamountain
The COVID-19 pandemic has impacted the daily lives of individuals across the world as multiple variants continue introducing new complexities. In December 2021, which is when we conducted our study, pressure to resume the normalcy of daily life was mounting as a new variant, Omicron, was rapidly spreading. A variety of at-home tests detecting SARS-CoV-2, known to the general public as “COVID tests,” were available for consumers to purchase. In this study, we conducted conjoint analysis utilizing an internet-based survey by presenting consumers (n = 583) with 12 different hypothetical at-home COVID test concepts that varied on five attributes (price, accuracy, time, where-to-buy, and method). Price was identified as the most important attribute, because participants were very price sensitive. Quick turnaround time and high accuracy were also identified as important. Additionally, although 64% of respondents were willing to take an at-home COVID test, only 22% reported they had previously taken the test. On December 21, 2021, President Biden announced the U.S. government would purchase 500 million at-home rapid tests and distribute them for free to Americans. Given the importance of price to participants, this policy of providing free at-home COVID tests was directionally appropriate.

2 August 2025 in BMC Global and Public Health
Verified
Journal Article
Open access
PDF file
KDKylie Dougherty
Kylie Dougherty
RKRebecca Kirby
Rebecca Kirby
KCKaterina Claud
Katerina Claud
KPKara Palamounta
Kara Palamounta
EAElizabeth Asma
Elizabeth Asma
LHLisa Hirschhorn
Lisa Hirschhorn
Preventing newborn deaths requires the right medical devices. However, in many countries, devices for small and sick newborn care (SSNC) are unavailable, not fit for the environment, or broken. Newborn Essential Solutions and Technologies (NEST360) is a multicountry alliance aimed at decreasing neonatal mortality in Kenya, Malawi, Nigeria, and Tanzania. The technology qualification, distribution, and management teams in NEST360 work to ensure appropriate devices are available and functional at facilities, by identifying needed technologies, sourcing suitable devices, testing them under varied conditions, establishing reliable supply chains, training staff, and maintaining the devices once installed through trained biomedical technicians. We applied implementation research (IR) to understand context, describe strategy selection, and implementation outcomes of the work designed to ensure the consistent availability of functional SSNC devices. Between March and July 2024, we conducted 12 in-depth interviews with NEST360 team members via Zoom, and reviewed quantitative programmatic data, including device functionality reports. We applied deductive content analysis for interviews and descriptive statistics for quantitative data. Results were used to develop an implementation research logic model (IRLM) using NEST360 and United Nations Children’s Fund SSNC Implementation Toolkit for contextual factors and the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework for implementation outcomes. We identified 40 contextual factors, 78% being barriers. Twenty-one strategies were implemented to address barriers to device qualification, distribution, and management efforts, including engaging stakeholders and conducting ongoing trainings. Notable implementation outcomes included reach with 29 devices in 12 product categories qualified, and all 66 facilities received NEST-qualified devices, effectiveness, in 2024, an average of 87% of all newborn care devices were functional, including those provided by NEST360 and those sourced through existing channels, adoption with over 2476 devices installed at NEST360 sites in 2023. Acceptability was also high with country-level biomedical technicians reporting positive facility-level experiences using the devices. The NEST360 approach to ensuring appropriate and functioning equipment for SSNC was successful through multiple strategies to address multilevel barriers. The use of IR facilitated understanding of how strategies addressed context and where change is needed. These results will be used in plans for scale-up and dissemination.